Alantra, the independent global mid-market investment banking firm, has advised the shareholders of Prescient Healthcare Group (Prescient), a global product strategy advisory firm serving the pharmaceutical and biotech industries, on an investment by Bridgepoint Development Capital, replacing current investor Baird Capital as the majority shareholder.
Founded in 2007, Prescient is headquartered in London and has offices in the US, India and China.
The business provides product strategy services to help its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients.
Prescient works with many multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharmaceutical organizations. Prescient has formed a partnership with Bridgepoint to support the continued scaling of its talent platform, client value proposition and global infrastructure.
Anthony Harrington and Tom Cowap, partner and director at Alantra, led the deal supported by vice president Ollie Hickley and associate Matthew Kumeta.
Anthony Harrington, partner at Alantra, commented: “The Prescient team have built a world-class insight and intelligence business in the pharma services sector. They have developed a distinctive, tech-enabled solution which combines data and analytics with strategic insights and advisory; they have successfully implemented a multi-national growth strategy; and they have proved adept at attracting talented employees. The team are poised to continue to deliver strong growth into the future and they have chosen an excellent partner to assist them in Bridgepoint Development Capital.”